GoodRx Q2 revenue beats estimates; raises 2026 outlook
GDRX•Outlook
- GoodRx raises full-year 2026 revenue guidance to $790 mln-$805 mln
- Company lifts full-year 2026 adjusted EBITDA forecast to $240 mln-$250 mln
- GoodRx expects lower unit economics to continue in the near term
Overview
- US medication savings platform's Q2 revenue fell 1% yr/yr but beat analyst expectations
- Adjusted EBITDA for Q2 beat analyst estimates; adjusted net income missed
- Company raised full-year 2026 revenue and adjusted EBITDA guidance
Result drivers
- Pharma Direct growth - Co said Pharma Direct revenue rose 76% yr/yr, driven by expanded market penetration with pharma manufacturers and GLP-1 access programs
- Subscription expansion - Subscription revenue grew 39% yr/yr, led by condition-specific programs such as weight loss and more subscription plans
- Prescription transactions decline - Prescription transactions revenue fell 26% yr/yr, due to fewer monthly active consumers, retail pharmacy changes, and a shift in investment toward subscriptions
